AMT-116 in Patients With Selected Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended
Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics,
pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors